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Strengths and limitations of this study
 ► Safety outcomes were limited due to the early ter-
mination of most of the included randomised con-
trolled trials (RCTs) and the inconsistent reporting of 
the adverse events.
 ► The quality of the included RCTs varied with more 
than half of the studies not reporting blinding of the 
participants.
 ► The study employed a comprehensive literature 
search of four databases.
 ► It used Bayesian estimation methods in the indirect 
comparisons of monoclonal antibodies and faecal 
microbiota transplantation to address the absence 
of head- to- head clinical trial evidence.
AbStrACt
Objectives The risk of recurrent Clostridium difficile 
infections (RCDIs) is high when treated with standard 
antibiotics therapy (SAT) alone. It is suggested that the 
addition of faecal microbiota transplantation (FMT) or 
bezlotoxumab after SAT reduces the risk of RCDI. In the 
absence of head- to- head randomised controlled trials 
(RCTs), this review attempts to compare the efficacy and 
safety of bezlotoxumab with FMT in reducing the risk of 
RCDI in hospitalised patients.
Design A systematic review and Bayesian network meta- 
analysis.
Data source A comprehensive search from inception 
to 30 February 2019 was conducted in four databases 
(Medline/PubMed, Embase, Scopus,  ClinicalTrials. gov).
Eligibility criteria RCTs reporting the resolution of 
diarrhoea associated with RCDI without relapse for at 
least 60 days after the end of treatments as the primary 
outcome.
Data extraction and synthesis We extracted author, 
year of publication, study design and binomial data that 
represented the resolution of diarrhoea or adverse events 
of monoclonal antibodies and FMT infusion. Random- 
effects models were used for resolution rate of RCDI and 
adverse events. The Cochrane Risk of Bias tool was used 
to assess the quality of included RCTs.
results Out of 1003 articles identified, seven RCTs 
involving 3043 patients contributed to the review. No 
difference was reported between single or multiple 
infusions of FMT and bezlotoxumab in resolving RCDI, 
(OR 1.53, 95% credible interval (CrI) 0.39 to 5.16) and 
(OR 2.86, 95% CrI 1.29 to 6.57), respectively. Patients 
treated with SAT alone or bezlotoxumab with SAT showed 
significantly lower rates of diarrhoea than FMT (OR 0, 95% 
CrI 0 to 0.09) and (OR 0, 95% CrI 0 to 0.19), respectively. 
There was no difference in terms of other adverse events.
Conclusions This is the first network meta- analysis that 
has compared the recently Food and Drug Administration- 
approved monoclonal antibody bezlotoxumab with FMT 
for resolving RCDI. The quality of the included RCTs 
was variable. The findings of this study suggested no 
difference between single or multiple infusions of FMT and 
bezlotoxumab. However, FMT was associated with a higher 
rate of non- serious diarrhoea as opposed to SAT used 
alone or in combination with bezlotoxumab.
bACkgrOunD
Clostridium difficile is considered to be the 
most common source of infectious diar-
rhoea in hospitalised patients.1 C. diffi-
cile- led infections (CDIs) are associated with 
high mortality particularly in the developed 
countries, including USA, Canada and 
Europe.2–4 Around 30% of the C. difficile- 
infected patients treated with standard anti-
biotics therapy (SAT), such as vancomycin, 
metronidazole or fidaxomicin, are reported 
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Table 1 PICOS strategy for clinical evidence of FMT and 
mAB in CDI
PICOS Clinical review
Population Adultswith primary or RCDI.
Intervention Studies that reported the efficacy and safety 
of FMT and/or mABs at any dosage form and 
via any route of administration in resolving 
RCDI.
Comparator Standard antibiotics therapy, such as 
vancomycin, metronidazole, orfidaxomicin, 
at any dosage form and via any route of 
administration.
Outcome The resolution of diarrhoea associated to CDI 
without relapse for, at least, 60 days after the 
end of treatments.
Adverse events.
Study design Published or unpublished randomised 
controlled trials of any size and duration.
CDI, Clostridium difficile infection; FMT, faecal microbiota 
transplantation; mAB, monoclonal antibody.
to develop recurrent CDIs (RCDIs) that increase up to 
60% with subsequent recurrences.5 This cyclic pattern of 
recurring CDI- inducing diarrhoea is triggered by the use 
of antibiotics and exotoxins produced by C. difficile that 
contributes to the weakening of the intrinsic faecal micro-
biota which serves as a natural host defense mechanism 
against C. difficile spores- led colonisation.5–7 The spore- 
forming ability of C. difficile is the main reason behind its 
nosocomial and community transmission.
Faecal microbiota transplantation (FMT) has been 
considered a novel intervention to replenish the intrinsic 
faecal microbiota barrier mechanism that protects against 
C. difficile- associated colonisation.8 Evidences from the 
meta- analyses of randomised controlled trials (RCTs) as 
well as observational studies have highlighted the benefits 
of FMT in resolving CDI over SAT alone.9–12 Furthermore, 
the current clinical practice guidelines by the Infectious 
Diseases Society of America (IDSA) and the Society for 
Healthcare Epidemiology of America recommend the 
use of FMT for the second or subsequent recurrences 
of CDI.13 However, the lack of a standardised product, 
dosage form and method of administration are some of 
the limitations of FMT.14
An alternative approach to FMT is to attenuate the 
effects of the exotoxins produced by C. difficile. Bezlo-
toxumab, a novel monoclonal antibody (mAB) that has 
been approved recently by the Food and Drug Adminis-
tration (FDA) in the USA, has been reported to reduce 
RCDI by attenuating the effect of exotoxin B when used 
in conjunction with SAT.15 16 However, there are no head- 
to- head clinical trials that have compared the efficacy and 
safety of FMT with bezlotoxumab in reducing the risk 
of RCDI. In the absence of any head- to- head trials, this 
systematic review and Bayesian network meta- analysis of 
RCTs aims to compare the efficacy and safety of bezlotox-
umab with FMT in reducing the risk of RCDI. The review 
would attempt to determine if FMT when compared with 
bezlotoxumab has better efficacy and safety in resolving 
the diarrhoea associated with CDI in hospitalised patients 
without relapse or not.
MEthOD
The systematic review and network meta- analysis were 
conducted according to the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses extension state-
ment for network meta- analyses.17
Patient and public involvement
Patients and public were not involved in the design, 
conducting and reporting of research.
Search strategy
A comprehensive search from inception to 30 February 
2019 was conducted in four databases (Medline/PubMed, 
Embase, Scopus,  ClinicalTrials. gov). Searches were 
conducted using Patients, Intervention, Comparator, 
Outcome and Study design strategy for clinical evidence 
of FMT and mAB in CDI (table 1) (see online supplemen-
tary file for the complete search strategy). Furthermore, 
manual searches were conducted to identify any addi-
tional studies by checking the reference lists of articles 
retrieved.
Outcome measure
The primary outcome of interest was the resolution of 
diarrhoea associated with CDI without relapse for at least 
60 days after the end of treatments. Furthermore, the 
adverse events of interest included diarrhoea, abdominal 
pain, leucocytosis, fatigue, nausea, fever, atrial fibrillation, 
dehydration, sepsis, tachycardia and infusion- specific 
reactions.
Inclusion and exclusion criteria
Both published as well as unpublished RCTs that assessed 
the efficacy and safety of FMT and bezlotoxumab in 
resolving CDI after a short course of SAT such as vanco-
mycin, metronidazole or fidaxomicin were eligible for 
inclusion. Studies were eligible for inclusion if they had 
included patients 18 years or older diagnosed with RCDI 
and reported the resolution rate of CDI as the efficacy 
outcome.
Data extraction, risk of bias and quality assessment
Two reviewers (EC and ANS) independently reviewed the 
titles and abstracts. Studies meeting the inclusion criteria 
were retrieved as full text to further assess their eligibility 
for inclusion. Reviewer, AAA, independently extracted 
data from included studies using a data extraction sheet 
(see table 2 for characteristics of included studies). 
Reviewer, ANS, checked all data extracted in the sheets. 
The data extracted included; author, year of publica-
tion, study design and clinical data reporting resolution 
outcomes of mABs and FMT infusion. The Cochrane 
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Figure 1 Study selection process using Preferred Reporting 
Items for Systematic Reviews and Meta- analyses. RCT, 
randomised controlled trial.
Figure 2 Network plot of included studies. Each circled 
node represents an intervention, the extent of the circle 
indicates the number of the included participants, the lines 
and their thickness represent direct comparisons and the 
number of studies included in each comparison, respectively. 
ACTBEZ, actoxumab plus bezlotoxumab; ACTO, actoxumab; 
BEZ, bezlotoxumab; FMT, faecal microbiota transplantation; 
SAT, standard antibiotics therapy.
Risk of Bias tool was used to assess the quality of included 
RCTs including randomisation, allocation concealment, 
blinding of participants, reporting of incomplete outcome 
data, selective reporting and any other bias.18 Other 
sources of bias explored included cross- contamination 
between- study groups, recruitment of participants from 
a selected population and non- compliance with the study 
protocol. For each included study, a risk of bias graphs 
and risk of bias summary were generated.
Statistical analysis
A Bayesian network meta- analysis was conducted using 
WinBUGS V.1.4.3 (MRC Biostatistics Unit, Cambridge, 
UK). Binomial data that represented the resolution of 
diarrhoea or adverse events were extracted and anal-
ysed. The binary outcomes were expressed as OR and 
95% credible interval (95% CrI) for resolution rate of 
RCDI and OR with 95% CrI for adverse events. ORs for 
treatment comparisons were estimated based on 20 000 
iterations, following the discarding of the first 10 000 
iterations in the model. Random- effects model was used 
for the resolution rate of RCDI and adverse events due 
to the assumed variability between the included studies. 
A binomial likelihood with a logit link was used in the 
model. Furthermore, non- informative priors were used 
for all parameters.Ranking probabilities of treatments 
were calculated using the surface under the cumula-
tive ranking curve (SUCRA) method. Additionally, a 
sensitivity analysis was conducted to exclude the studies 
and/or patients who received non- FDA- approved mAB. 
Furthermore, a pairwise meta- analysis was conducted to 
check for heterogeneity.
rESultS
The initial search identified 1003 studies (see figure 1). 
Fifteen duplicates along with an additional 631 studies 
were removed at title level due to not meeting the inclu-
sion criteria. The abstracts of remaining 357 studies 
were reviewed, of which a further 297 were excluded. 
Full texts of the remaining 60 studies were reviewed. Of 
these, further 53 studies were excluded based on the 
inclusion and exclusion criteria. The remaining 7 RCTs 
with 3043 patients contributed to the review and network 
meta- analysis.
Characteristics of included studies
The seven included studies (see table 2 for characteristics 
of included studies) were published between 2010 and 
2017 and involved 3043 patients.9 12 15 16 19–21 Four open- 
labelled RCTs involving 139 patients reported compari-
sons of FMT versus vancomycin alone in patients with an 
initial episode of CDI or with RCDI and followed for at 
least 70 days following the end of the treatments.9 12 19 21 
Patients assigned to the FMT arm received an initial course 
of vancomycin ranging from 3 to 14 days to assure that 
patients were covered with an antibiotic therapy at the 
time of donor screening.
All studies involving FMT used fresh faeces from 
related donors. The time for infusing the fresh FMT 
from the time of defaecation varied across studies from 
3.1 to 48 hours. Three FMT studies were terminated early 
following an interim analysis; two because of the observed 
superiority of the FMT9 12 and one because of inferiority.19 
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Figure 3 (A) Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 
included studies. (B) Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
A fourth study was underpowered and was considered a 
pilot study.21 In two studies,9 12 FMT was reinfused in some 
patients who experienced a recurrence after the first infu-
sion. In the remaining two studies, FMT was used as a 
single infusion.19 21
Three double- blinded, placebo- controlled RCTs 
including two multicentre phase II studies and one multi-
national, multicentre phase III study investigated the 
efficacy of mABs.15 16 20 The two phase two studies inves-
tigated the safety and efficacy of newly developed mABs 
against C. difficile exotoxins A and B that corroborated 
prior evidence of the role of these exotoxins in the viru-
lence of C. difficile.6 The third RCT confirmed that antag-
onising toxin B is the main determinant in suppressing 
the virulence of C. difficile, however, it could not rule 
out the role of toxin A.7 Three regimens of mABs were 
tested in these RCTs: antitoxin A (actoxumab), antitoxin 
B (bezlotoxumab) and a combination of both, all of 
which were infused as a single dose of 10 mg/kg either 
during or right away after a course of SAT. It is important 
to highlight that only bezlotoxumab was approved by the 
FDA for this indication (see figure 2 for network plot of 
included studies).
Study quality
The quality of the studies was variable (see figure 3A,B). 
Only three of the seven studies used blinding of partici-
pants.15 16 20
Comparative efficacy of FMt and mAbs in reducing rCDI
The initial analysis comparing the resolution of CDI after 
receiving one FMT infusion or any mAB regimen found 
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Figure 4 Rankograms show the ranking of interventions from the best to the worst based on the corresponding surface under 
the cumulative ranking curve (SUCRA) probability in the random- effect models.
Table 3 Network meta- analysis of the relative efficacy of mABs and single or multiple infusions of FMT for CDI resolution
FMT 1.29
(0.34–3.93)
1.53
(0.39–5.16)
2.61
(0.64–9.74)
2.98
(1.13–7.53)
2.10
(0.28–15.99)
Actoxumab-
bezlotoxumab
1.17
(0.50–3.12)
2.01
(0.74–6.42)
2.28
(1.15–5.52)
2.58
(0.30–23.53)
1.22
(0.24–6.66)
Bezlotoxumab 1.71
(0.57–5.49)
1.93
(0.84–4.91)
4.55
(0.49–45.11)
2.14
(0.33–15.50)
1.75
(0.24–13.43)
Actoxumab 1.14
(0.42–3.10)
5.22
(1.26–23.25)
2.46
(0.62–10.68)
2.01
(0.40–10.51)
1.16
(0.20–6.39)
Standard antibiotic therapy
  Treatment  Multiple infusions of FMT, OR (95% CrI)  Single infusion of FMT, OR (95% CrI).
CDI, Clostridium difficile infection; CrI, credible interval; FMT, faecal microbiota transplantation; mABs, monoclonal antibodies.
no statistical difference between FMT and bezlotoxumab 
(OR 1.53, 95% CrI 0.39 to 5.16). Yet, FMT showed the 
best SUCRA probability (63.6%) (see figure 4). In addi-
tion, FMT showed better resolution of CDI than SAT 
(OR 2.98, 95% CrI 1.13 to 7.53). Whereas, bezlotoxumab 
showed no statistical difference in resolution of CDI than 
SAT (OR 1.93, 95% CrI 0.84 to 4.91) (see table 3).
A secondary comparative analysis that included the 
resolution outcomes reported for patients who received 
two or more FMT infusions or any mAB regimen was 
conducted. FMT did not show statistical difference in 
resolution of CDI than bezlotoxumab (OR 2.58, 95% 
CrI 0.30 to 23.53). In addition, bezlotoxumab showed no 
statistical difference in resolution of CDI than SAT (OR 
2.01, 95% CrI 0.40 to 10.51) However, FMT showed better 
resolution of CDI than SAT (OR 5.22, 95% CrI 1.26 to 
23.25) (see table 3).
The analyses of the safety data for FMT, bezlotoxumab 
and SAT revealed a significantly lower rate of non- serious 
diarrhoea in patients receiving bezlotoxumab (OR 0, 
95% CrI 0 to 0.19) and SAT (OR 0, 95% CrI 0 to 0.09), 
compared with patients treated with FMT. There were no 
differences on other adverse events.
Sensitivity analysis
A sensitivity analysis was conducted by excluding the 
resolution outcomes of patients who received non- FDA- 
approved mABs. There was no difference between single 
or multiple FMT infusion and bezlotoxumab (OR 1.61, 
95% CrI 0.19 to 12.69), (OR 2.90, 95% CrI 0.20 to 45.35), 
respectively. However, FMT showed the best SUCRA prob-
ability (79.7%). The pairwise meta- analysis suggested that 
heterogeneity I2 for SAT versus FMT and for SAT versus 
mABs was high which indicated high variability between 
the studies.
DISCuSSIOn
To the best of authors’ knowledge, this is the first network 
meta- analysis that has compared the recently FDA- 
approved monoclonal antibody bezlotoxumab with FMT 
for resolving RCDI. The findings of this study suggested 
that single or multiple infusions of FMT showed no differ-
ence in efficacy than a single infusion of bezlotoxumab. 
However, FMT was associated with a higher rate of non- 
serious diarrhoea.
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Despite the inconsistency in the results of the four RCTs 
that studied FMT versus SAT in resolving RCDI,9 12 19 21 
the network analysis showed the superiority of FMT over 
SAT alone. This is consistent with the findings of previous 
meta- analyses of RCTs and observational studies.10 11 The 
inconsistency in the results of the four included studies 
may be attributed to their small sample sizes, lack of 
blinding and variability between them on the basis of the 
process of collecting donor faeces, preparation of FMT, 
lag time between faeces collection and infusion, method 
of administration and SAT regimen. Furthermore, as 
evident from the findings of a previous RCT, patients 
who received FMT monotherapy for an initial episode 
of CDI without receiving prior antibiotics, retained more 
bacteroidetes in their gut than patients treated with anti-
biotics.22 These findings confirm the effect of antibiotics 
in attenuating intrinsic microbiota.5 It may also explain 
the inferiority of FMT over SAT in the study when FMT 
was preceded by 14 days of antibiotics.19 On the contrary, 
administration of FMT earlier (after the second recur-
rence of CDI) as opposed to a late administration (after 
the third or subsequent recurrences) led to shorter 
length of hospital stay and fewer visits to the emergency 
department.23 Thus, the differences in the results of the 
individual studies included in the current network meta- 
analysis could have been due to the variability in starting 
FMT for initial CDI or RCDI and the inconsistency in 
the number of previous recurrences among included 
patients.
Bezlotoxumab showed a favourable efficacy and safety 
profile in preventing RCDI in two robust prospective, 
double- blinded, placebo- controlled RCTs.16 24 Further-
more, the effect was sustained throughout the 3- month 
follow- up.16 Bezlotoxumab has a novel mechanism of 
action that reduces the possibility of RCDI, yet its high 
cost may limit its utilisation.16 24 Furthermore, even 
though the network meta- analysis did not report any 
difference in the resolution rate between bezlotoxumab 
and FMT, the SUCRA probability score favoured FMT in 
the rankogram.
This review had some limitaions. The quality of the 
included RCTs was variable with more than half of the 
studies not reporting blinding of the participants. 
Furthermore, the RCTs studying FMT differed in design, 
donor selection, FMT preparation, follow- up time, lag 
time between faeces collection and infusion and lag time 
between antibiotics discontinuation and FMT infusion; 
while mABs were infused either during or right away after 
the discontinuation of antibiotics. None of the included 
RCTs reported the number of previous recurrences. 
Furthermore, safety outcomes were limited due to the 
early termination of most of the included RCTs and the 
inconsistent reporting of the adverse events. Neverthe-
less, the review employed a rigorous and comprehensive 
search strategy to identify relevant studies. Furthermore, 
it used the Bayesian estimation methods in the indirect 
comparisons of mABs and FMT to address the absence 
of head- to- head clinical trial evidence. By doing so, this 
review addressed a significant issue identified in the 
2017 IDSA13 guidelines by filling the gap in information 
concerning the best method in preventing RCDI and the 
role of FMT and mABs therapies. However, further studies 
are required to assess the efficacy, safety, cost and clinical 
implications of multiple infusions of bezlotoxumab.
COnCluSIOn
Single of multiple infusions of FMT showed no differ-
ence in efficacy than single infusion of bezlotoxumab 
in resolving RCDI but with a higher rate of non- serious 
diarrhoea. Further studies are needed to investigate the 
efficacy and safety of using FMT as monotherapy for CDI, 
the possible attenuating effect of short- course antibi-
otics given before FMT and the clinical implications of 
multiple infusions of bezlotoxumab.
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